| __timestamp | Celldex Therapeutics, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20622000 | 7751000 |
| Thursday, January 1, 2015 | 33837000 | 10251000 |
| Friday, January 1, 2016 | 35979000 | 9575000 |
| Sunday, January 1, 2017 | 25003000 | 10912000 |
| Monday, January 1, 2018 | 19269000 | 11049000 |
| Tuesday, January 1, 2019 | 15426000 | 11646000 |
| Wednesday, January 1, 2020 | 14456000 | 13265000 |
| Friday, January 1, 2021 | 20488000 | 25805000 |
| Saturday, January 1, 2022 | 27195000 | 35182000 |
| Sunday, January 1, 2023 | 30914000 | 94999000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc. have been navigating this financial landscape since 2014. Over the past decade, Celldex has maintained a relatively stable SG&A expense, averaging around $24 million annually. In contrast, Viridian's SG&A costs have surged, peaking at $95 million in 2023, a staggering 12-fold increase from 2014. This dramatic rise highlights Viridian's aggressive expansion strategy, while Celldex's more conservative approach reflects a focus on cost efficiency. As these companies continue to evolve, their ability to manage SG&A expenses will be pivotal in determining their long-term success. Investors and stakeholders should closely monitor these trends to gauge each company's operational efficiency and strategic direction.
Amgen Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Celldex Therapeutics, Inc.
Breaking Down SG&A Expenses: Zoetis Inc. vs Celldex Therapeutics, Inc.
Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Ascendis Pharma A/S or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Verona Pharma plc vs Celldex Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and Viridian Therapeutics, Inc.
Protagonist Therapeutics, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs Celldex Therapeutics, Inc.
Ligand Pharmaceuticals Incorporated and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared
Amphastar Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Celldex Therapeutics, Inc. and MiMedx Group, Inc.